Cold Chain Platform’s CEO, Linda Kim, interviews Hedley Rees on Cell and Gene Therapy Supply Chain
Some real supply chain writings again!
Turning back to my roots
Today, I’m turning back to my roots in professional management of biopharmaceutical supply chains. C19 has been so all-absorbing, that I’d forgotten what it was like to write for people trying to achieve meaningful ends in the industry—yes, they do exist.
This article was first published in Cold Chain Platform, based in South Korea:
Interview with Hedley Rees on Cell and Gene Therapy Supply Chain (please excuse my naked legs, it was towards the end of summer!)
In September 2022, CCP’s CEO, Linda Kim had the pleasure of sitting down with Hedley Rees, Managing Director, PharmaFlow Limited to discuss current Cell and Gene Therapy Supply Chain challenges, and developments in the future:
1. What can you tell us about cell and gene therapies?
Cell therapy refers to the transfer of cells into a patient with the goal of improving a disease. The earliest and most established cell therapy is the blood transfusion. Gene therapy seeks to modify or manipulate the expression of a…